Tofacitinib for treating juvenile idiopathic arthritis

2.1 Tofacitinib (Xeljanz, Pfizer) is indicated for: 'the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive or negative polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs'.

2.2 Tofacitinib can be used with methotrexate, or as monotherapy when methotrexate is not tolerated or if continued treatment with methotrexate is inappropriate.

2.3 The dosage schedule is available in the summary of product characteristics.

2.4 The list price of a 56‑tablet pack of 5 mg tofacitinib is £690.03 (excluding VAT; BNF online accessed August 2021). Tofacitinib is also available as an oral 1 mg/ml solution in 240 ml bottles.

2.5 The company has a commercial arrangement. This makes tofacitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.